Sue-Ann-Marie Tracy, APRN
Family · Pensacola, FLNPI 1144956418
Payments from drug & device makers
Across 140 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$375
- Novo Nordisk$328
- Pfizer$262
- AstraZeneca$260
- Lilly USA, LLC$223
- Sumitomo Pharma America, Inc.$201
- plus $2K from 20 others
What the payments were for
- Food & beverage$2,97291%
- Education$2839%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $375 |
| Novo Nordisk | 17 | $328 |
| Pfizer | 14 | $262 |
| AstraZeneca | 13 | $260 |
| Lilly USA, LLC | 13 | $223 |
| Sumitomo Pharma America, Inc. | 9 | $201 |
| Johnson & Johnson | 5 | $187 |
| AbbVie | 9 | $170 |
| Exact Sciences | 8 | $156 |
| GSK | 8 | $136 |
| Edwards Lifesciences | 1 | $134 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Amgen | 7 | $114 |
| Bayer | 3 | $100 |
| Sanofi-aventis U.S. LLC | 3 | $76 |
| Boehringer Ingelheim | 3 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $55 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Dexcom, Inc. | 1 | $28 |
| Merck | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Metacel Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,255 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $65,608 |
| OzempicSemaglutide | 26 | $51,119 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $31,085 |
| MounjaroTirzepatide | 15 | $30,878 |
| JardianceEmpagliflozin | 27 | $29,187 |
| Spiriva RespimatTiotropium Bromide | 22 | $22,428 |
| FarxigaDapagliflozin Propanediol | 13 | $19,658 |
| JanuviaSitagliptin Phosphate | 17 | $18,040 |
| XareltoRivaroxaban | 17 | $12,058 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,829 |
| Repatha SureclickEvolocumab | 11 | $5,935 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $5,583 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,578 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $4,386 |
| Desloratadine | 72 | $2,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $262 | $65,60862 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $63 | $57,19361 claims |
| Novo NordiskOzempic | $328 | $51,11926 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $136 | $39,91533 claims |
| Lilly USA, LLCMounjaro | $223 | $30,87815 claims |
| AstraZenecaFarxiga | $260 | $19,65813 claims |
| MerckJanuvia | $27 | $18,04017 claims |
| Johnson & JohnsonXarelto | $187 | $12,05817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Pensacola
- Brittany PerezPensacola$130K
- Mary AanestadPensacola$54K
- Raymond HalsteadPensacola$50K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.